These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets. Lang S; Bruderek K; Kaspar C; Höing B; Kanaan O; Dominas N; Hussain T; Droege F; Eyth C; Hadaschik B; Brandau S Clin Cancer Res; 2018 Oct; 24(19):4834-4844. PubMed ID: 29914893 [No Abstract] [Full Text] [Related]
5. Expansion of PMN-myeloid derived suppressor cells and their clinical relevance in patients with oral squamous cell carcinoma. Zhong LM; Liu ZG; Zhou X; Song SH; Weng GY; Wen Y; Liu FB; Cao DL; Liu YF Oral Oncol; 2019 Aug; 95():157-163. PubMed ID: 31345384 [TBL] [Abstract][Full Text] [Related]
6. In Vitro Generation of Human Neutrophilic Myeloid-Derived Suppressor Cells. Singh A; Rieber N Methods Mol Biol; 2021; 2236():77-83. PubMed ID: 33237542 [TBL] [Abstract][Full Text] [Related]
7. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential. Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030 [TBL] [Abstract][Full Text] [Related]
8. Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation. Cassetta L; Bruderek K; Skrzeczynska-Moncznik J; Osiecka O; Hu X; Rundgren IM; Lin A; Santegoets K; Horzum U; Godinho-Santos A; Zelinskyy G; Garcia-Tellez T; Bjelica S; Taciak B; Kittang AO; Höing B; Lang S; Dixon M; Müller V; Utikal JS; Karakoç D; Yilmaz KB; Górka E; Bodnar L; Anastasiou OE; Bourgeois C; Badura R; Kapinska-Mrowiecka M; Gotic M; Ter Laan M; Kers-Rebel E; Król M; Santibañez JF; Müller-Trutwin M; Dittmer U; de Sousa AE; Esendağlı G; Adema G; Loré K; Ersvær E; Umansky V; Pollard JW; Cichy J; Brandau S J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32907925 [TBL] [Abstract][Full Text] [Related]
9. Immunophenotyping of Circulating Myeloid-Derived Suppressor Cells (MDSC) in the Peripheral Blood of Cancer Patients. Bruderek K; Schirrmann R; Brandau S Methods Mol Biol; 2021; 2236():1-7. PubMed ID: 33237535 [TBL] [Abstract][Full Text] [Related]
10. Phenotypic Characterization and Isolation of Myeloid-Derived Suppressor Cells. Reuven O; Mikula I; Ashkenazi-Preiser H; Twaik N; Ben-Meir K; Meirow Y; Daniel L; Kariv G; Kurd M; Baniyash M Curr Protoc; 2022 Oct; 2(10):e561. PubMed ID: 36214619 [TBL] [Abstract][Full Text] [Related]
11. PMN-MDSC Frequency Discriminates Active Versus Latent Tuberculosis and Could Play a Role in Counteracting the Immune-Mediated Lung Damage in Active Disease. Grassi G; Vanini V; De Santis F; Romagnoli A; Aiello A; Casetti R; Cimini E; Bordoni V; Notari S; Cuzzi G; Mosti S; Gualano G; Palmieri F; Fraziano M; Goletti D; Agrati C; Sacchi A Front Immunol; 2021; 12():594376. PubMed ID: 33981297 [TBL] [Abstract][Full Text] [Related]
12. Flow cytometry-based immunophenotyping of myeloid-derived suppressor cells in human breast cancer patient blood samples. Lee EJ; Jung S; Park KH; Park SI J Immunol Methods; 2022 Nov; 510():113348. PubMed ID: 36058258 [TBL] [Abstract][Full Text] [Related]